The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis.
Saved in:
| Title: | The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. |
|---|---|
| Authors: | Kivitz A; Department of Rheumatology, Altoona Center for Clinical Research, Altoona, Pennsylvania, USA., Wang L; Horizon Therapeutics plc, Rockville, Maryland, USA., Alevizos I; Horizon Therapeutics plc, Rockville, Maryland, USA., Gunsior M; Horizon Therapeutics plc, Rockville, Maryland, USA., Falloon J; Horizon Therapeutics plc, Rockville, Maryland, USA., Illei G; Horizon Therapeutics plc, Rockville, Maryland, USA.; IRD Biomedical Consulting, LLC, Rockville, Maryland, USA., St Clair EW; Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA stcla003@mc.duke.edu. |
| Source: | RMD open [RMD Open] 2023 Aug; Vol. 9 (3). |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101662038 Publication Model: Print Cited Medium: Internet ISSN: 2056-5933 (Electronic) Linking ISSN: 20565933 NLM ISO Abbreviation: RMD Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2056-5933 |
|---|---|
| DOI: | 10.1136/rmdopen-2023-003317 |
